XTX Topco’s Myriad Genetics MYGN Stock Holding History

XTX Topco’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.35M	Buy	237,024 +132,656	+127%	+$602K	0.02%	1502
2026 Q1	$470K	Buy	+104,368	New	+$544K	0.01%	2104
2025 Q3	–	Sell	-284,357	Closed	-$1.51M	–	3025
2025 Q2	$1.51M	Buy	284,357 +263,147	+1,241%	+$1.55M	0.06%	451
2025 Q1	$188K	Sell	21,210 -42,870	-67%	-$515K	0.01%	1717
2024 Q4	$879K	Buy	64,080 +52,923	+474%	+$977K	0.07%	374
2024 Q3	$306K	Sell	11,157 -1,370	-11%	-$37.1K	0.02%	1168
2024 Q2	$306K	Buy	+12,527	New	+$275K	0.03%	948
2023 Q3	–	Sell	-9,825	Closed	-$228K	–	1850
2023 Q2	$228K	Buy	+9,825	New	+$214K	0.04%	924
2021 Q2	–	Sell	-9,974	Closed	-$304K	–	995
2021 Q1	$304K	Buy	+9,974	New	+$283K	0.15%	267

Other funds holding MYGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

XTX Topco's MYGN Position: Q2 2026 in Review

XTX Topco increased its Myriad Genetics (MYGN) stake by 127% in Q2 2026, buying an estimated $602K and bringing the position to 237,024 shares worth $1.35M. The position accounts for 0.02% of the portfolio, ranked #1502.

XTX Topco first reported a position in MYGN in Q1 2021 and has held it in 9 quarters since. The position peaked at $1.51M in Q2 2025. 196 funds tracked by Wall St. Rank hold MYGN as of Q2 2026.

XTX Topco held 237,024 shares of Myriad Genetics worth $1.35M as of Q2 2026.
XTX Topco bought 132,656 Myriad Genetics shares in Q2 2026, an estimated $602K.
Myriad Genetics made up 0.02% of XTX Topco's portfolio in Q2 2026, its #1502 holding.
XTX Topco first reported a position in Myriad Genetics in Q1 2021 and has held it in 9 quarters since.
XTX Topco's Myriad Genetics position peaked at $1.51M in Q2 2025.
196 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2026.

Based on XTX Topco's 13F filing for Q2 2026, filed 14 Aug 2026.